Treatment of neuroendocrine tumors with somatostatin analogs

被引：10

作者：

Janson E.T. ^{[1
]}

机构：

[1] Department of Medical Sciences, Endocrine Oncology, Uppsala University Hospital

来源：

Pituitary | 2006年 / 9卷 / 3期

关键词：

Hormone secretion; Neuroendocrine; Somatostatin analog; Treatment;

D O I：

10.1007/s11102-006-0271-4

中图分类号：

学科分类号：

摘要：

Neuroendocrine tumors constitute a group of hormone producing tumors originating from neuroendocrine cells in different organs. Most tumors have a low proliferation index measured by Ki67 and the progression of the tumor is slow. However, many patients suffer from endocrine symptoms induced by the hormones produced and released by the tumor cells. For some patients these symptoms can be life- threatening as in midgut carcinoid patients suffering from carcinoid crises with extensive flushes and hypotension or in patients with severe diarrhea induced by tumors producing vasointestinal polypeptide. In many other patients the hormone-induced symptoms interfere with the ability to carry out ordinary daily activities. The introduction of somatostatin analogs in the treatment of these hormone related symptoms has made it possible to control most of them and has added significantly to the quality of life for this group of patients. Unfortunately, the clinical inhibitory effect on tumor growth has not been very good with only 5-10% of the patients showing an objective response. However, stabilization of tumor growth may be achieved in a significant number of patients. In the future, the hope is that development of new somatostatin analogs with broader receptor-binding profiles will give us new analogs which are more efficient with regard to their antiproliferative effect. This possibility will be studied in future trials. © Springer Science + Business Media, LLC 2006.

引用

页码：249 / 256

页数：7

共 54 条

[1]

Kloppel G., Perren A., Heitz P.U., The gastroenteropancreatic neuroendocrine cell system and its tumors. The WHO classification, Ann NY Acad Sci, 1014, (2004)

[2]

Spread C., Berkel H., Jewell L., Jenkins H., Yakimets W., Colon carcinoid tumors. A population based study, Dis Colon Rectum, 37, (1994)

[3]

Koura A.N., Giacco G.G., Curley S.A., Skibber J.M., Feig B.W., Ellis L.M., Carcinoid tumors of the rectum. Effect of size, histopathology, and surgical treatment on metastasis free survival, Cancer, 79, (1997)

[4]

Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R., Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone, Science, 179, (1973)

[5]

Patel Y.C., Molecular pharmacology of somatostatin receptor subtypes, J Endocrinol Investig, 20, (1997)

[6]

de Herder W.W., Lamberts S.W.J., Somatostatin and somatostatin analogues: Diagnostic and therapeutic uses, Curr Opin Oncol, 14, (2002)

[7]

Susini C., Buscail L., Rationale for the use of somatostatin analogs as antitumor agents, Ann Oncol, (2006)

[8]

Grant M., Colliers B., Kumar U., Agonist-dependent dissociation of human somatostatin receptor 2 dimers, J Biol Chem, 279, (2004)

[9]

Thulin L., Samnegard H., Tyden G., Long D.H., Efendic S., Efficacy of somatostatin in a patient with carcinoid syndrome, The Lancet, 2, (1978)

[10]

Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P., Petcher T.J., Pless J., SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action, Life Sci, 31, (1982)

← 1 2 3 4 5 6 →